Top

Virology Journal

Published in:

Open Access 01-12-2014 | Short report

Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines

Authors: Tila Khan, Connie L Heffron, Kevin P High, Paul C Roberts

Published in: Virology Journal | Issue 1/2014

Abstract

Background

Potent and safe adjuvants are needed to improve the efficacy of parenteral and mucosal vaccines. Cytokines, chemokines and growth factors have all proven to be effective immunomodulatory adjuvants when administered with a variety of antigens. We have previously evaluated the efficacy of membrane-anchored interleukins (IL) such as IL-2 and IL-4 co-presented as Cytokine-bearing Influenza Vaccines (CYT-IVACs) using a mouse model of influenza challenge.

Findings

Here, we describe studies evaluating the parenteral and mucosal adjuvanticity of membrane-bound IL-12 and IL-23 CYT-IVACs in young adult mice. Mucosal immunization using IL-12 and IL-23 bearing whole influenza virus vaccine (WIV) was more effective at eliciting virus-specific nasal IgA and reducing viral lung burden following challenge compared to control WIV vaccinated animals. Both IL-12 and IL-23 bearing WIV elicited the highest anti-viral IgA levels in serum and nasal washes.

Conclusions

This study highlights for the first time the mucosal adjuvant potential of IL-12 and IL-23 CYT-IVAC formulations in eliciting mucosal immune responses and reducing viral lung burden. The co-presentation of immunomodulators in direct context with viral antigen in whole inactivated viral vaccines may provide a means to significantly lower the dose of vaccine required for protection.

Available only for authorised users

Furuya Y: Return of inactivated whole-virus vaccine for superior efficacy. Immunol Cell Biol. 2011, 90: 571-578.PubMedCrossRef

Palese P: Making better influenza virus vaccines?. Emerg Infect Dis. 2006, 12: 61-65. 10.3201/eid1201.051043.PubMedPubMedCentralCrossRef

Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H: Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine. 2003, 21: 3212-3218. 10.1016/S0264-410X(03)00234-2.PubMedCrossRef

Tumpey TM, Renshaw M, Clements JD, Katz JM: Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza a H5N1 virus infection. J Virol. 2001, 75: 5141-5150. 10.1128/JVI.75.11.5141-5150.2001.PubMedPubMedCentralCrossRef

Stephenson I, Gust I, Pervikov Y, Kieny MP: Development of vaccines against influenza H5. Lancet Infect Dis. 2006, 6: 458-460. 10.1016/S1473-3099(06)70528-X.PubMedCrossRef

Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR: IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol. 1999, 162: 122-128.PubMed

Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E: A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine. 1999, 17: 1223-1238. 10.1016/S0264-410X(98)00346-6.PubMedCrossRef

Thompson AL, Staats HF: Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol. 2011, 2011: 289597-PubMedPubMedCentralCrossRef

Arulanandam BP, O’Toole M, Metzger DW: Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999, 180: 940-949. 10.1086/314996.PubMedCrossRef

10.

Kodama S, Hirano T, Noda K, Abe N, Suzuki M: A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. Vaccine. 2010, 28: 2510-2516. 10.1016/j.vaccine.2010.01.043.PubMedCrossRef

11.

Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Perry HC, Davies ME, Shiver JW, Letvin NL: Potent CD4(+) T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol. 2002, 168: 562-568. 10.4049/jimmunol.168.2.562.PubMedCrossRef

12.

Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A: Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine. 2008, 26: 2350-2359. 10.1016/j.vaccine.2008.02.063.PubMedCrossRef

13.

Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A: Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi Viruses. 2008, 2: 41-51. 10.1111/j.1750-2659.2008.00038.x.CrossRef

14.

Yang YF, Leggat D, Herbert A, Roberts PC, Sundick RS: A Novel Method to Incorporate Bioactive Cytokines as Adjuvants on the Surface of Virus Particles. J Interferon Cytokine Res. 2009, 29: 9-22. 10.1089/jir.2008.0017.PubMedPubMedCentralCrossRef

15.

Herbert AS, Heffron L, Sundick R, Roberts PC: Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge. Virol J. 2009, 6: 42-10.1186/1743-422X-6-42.PubMedPubMedCentralCrossRef

16.

Watford WT, Moriguchi M, Morinobu A, O’Shea JJ: The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003, 14: 361-368. 10.1016/S1359-6101(03)00043-1.PubMedCrossRef

17.

Trinchieri G: Interleukin-12 and its role in the generation of TH1 cells. Immunol Today. 1993, 14: 335-338. 10.1016/0167-5699(93)90230-I.PubMedCrossRef

18.

Lynch JM, Briles DE, Metzger DW: Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun. 2003, 71: 4780-4788. 10.1128/IAI.71.8.4780-4788.2003.PubMedPubMedCentralCrossRef

19.

Bradney CP, Sempowski GD, Liao HX, Haynes BF, Staats HF: Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol. 2002, 76: 517-524. 10.1128/JVI.76.2.517-524.2002.PubMedPubMedCentralCrossRef

20.

Staats HF, Bradney CP, Gwinn WM, Jackson SS, Sempowski GD, Liao HX, Letvin NL, Haynes BF: Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol. 2001, 167: 5386-5394. 10.4049/jimmunol.167.9.5386.PubMedCrossRef

21.

Khan T, Heffron CL, High KP, Roberts PC: Tailored Vaccines Targeting the Elderly Using Whole Inactivated Influenza Vaccines Bearing Cytokine Immunomodulators. J Interferon Cytokine Res. 2014, 34: 129-139. 10.1089/jir.2012.0119.PubMedPubMedCentralCrossRef

22.

Belladonna ML, Renauld JC, Bianchi R, Vacca C, Fallarino F, Orabona C, Fioretti MC, Grohmann U, Puccetti P: IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol. 2002, 168: 5448-5454. 10.4049/jimmunol.168.11.5448.PubMedCrossRef

23.

Peng LS, Penichet ML, Dela Cruz JS, Sampogna SL, Morrison SL: Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). J Interferon Cytokine Res. 2001, 21: 709-720. 10.1089/107999001753124444.PubMedCrossRef

24.

Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W: Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine. 2008, 26: 6555-6563. 10.1016/j.vaccine.2008.09.057.PubMedCrossRef

25.

Muhamed G, Greenbaum E, Zakay-Rones Z: Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Isr Med Assoc J. 2006, 8: 155-158.PubMed

26.

Clements ML, Odonnell S, Levine MM, Chanock RM, Murphy BR: Dose-responses of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers-role of local antibody in resistance to infection with vaccine virus. Infect Immun. 1983, 40: 1044-1051.PubMedPubMedCentral

27.

Enioutina EY, Visic D, Daynes RA: The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine. 2000, 18: 2753-2767. 10.1016/S0264-410X(00)00059-1.PubMedCrossRef

28.

Liard C, Munier S, Arias M, Joulin-Giet A, Bonduelle O, Duffy D, Shattock RJ, Verrier B, Combadiere B: Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine. 2011, 29: 6379-6391. 10.1016/j.vaccine.2011.04.080.PubMedCrossRef

29.

Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA: Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology. 2008, 381: 106-115. 10.1016/j.virol.2008.08.019.PubMedCrossRef

30.

Faulkner L, Buchan G, Slobbe L, Lockhart E, Wales J, Wilson M, Baird M: Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection. Vaccine. 2003, 21: 932-939. 10.1016/S0264-410X(02)00543-1.PubMedCrossRef

31.

Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Bérard N: Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 2009, 10: 778-785.PubMedCrossRef

32.

Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL, Le TV, Lorenz RG, Xu H, Kolls JK, Carter RH, Chaplin DD, Williams RW, Mountz JD: Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2008, 9: 166-175. 10.1038/ni1552.PubMedCrossRef

33.

Jaffar Z, Ferrini ME, Herritt LA, Roberts K: Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol. 2009, 182: 4507-4511. 10.4049/jimmunol.0900237.PubMedPubMedCentralCrossRef

34.

Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, Roffler SR, Chiang BL, Lee CN, Wu CW, Tao MH: Antitumor and antimetastatic activity of IL-23. J Immunol. 2003, 171: 600-607. 10.4049/jimmunol.171.2.600.PubMedCrossRef

35.

Oppmann B, Lesley R, Blom B, Timans JC, Xu YM, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000, 13: 715-725. 10.1016/S1074-7613(00)00070-4.PubMedCrossRef

36.

Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C: Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 2006, 66: 6395-6404. 10.1158/0008-5472.CAN-05-4087.PubMedCrossRef

37.

Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M: IL-23 promotes tumour incidence and growth. Nature. 2006, 442: 461-465. 10.1038/nature04808.PubMedCrossRef

Title: Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines
Authors: Tila Khan
Connie L Heffron
Kevin P High
Paul C Roberts
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2014
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-11-78

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines

Abstract

Background

Findings

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Findings

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Genetic heterogeneity of swine hepatitis E virus isolates from Yunnan province, China in 2011–2012

Molecular investigation of bovine viral diarrhea virus infection in yaks (Bos gruniens) from Qinghai, China

Genetic heterogeneity of hepatitis C virus cell entry receptors seems to have no influence on selection of virus variants

The CD8 Antiviral Factor (CAF) can suppress HIV-1 transcription from the Long Terminal Repeat (LTR) promoter in the absence of elements upstream of the CATATAA box

Molecular detection of human rhinoviruses in respiratory samples: a comparison of Taqman probe-, SYBR green I- and BOXTO-based real-time PCR assays

Identification of linear human B-cell epitopes of tick-borne encephalitis virus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page